PDF(Pubmed)
Abstract：
Autoimmune hepatitis (AIH) is a rare chronic liver disease affecting annually 100,000-200,000 individuals in the United States. The first-line therapy in AIH is azathioprine and corticosteroids. However, adverse events may occur, which can preclude disease remission. In these cases, mycophenolate, mercaptopurine, and tacrolimus can be used. Rituximab is offered in difficult to treat cases. Sirolimus is an alternative regimen. However, little is known about its use in AIH. This is a challenging case of \"difficult to treat\" AIH managed with sirolimus and rituximab, after multiple unsuccessful trials with other medications.
摘要：
自身免疫性肝炎（AIH）是一种罕见的慢性肝病，在美国每年影响100,000-200,000个人。AIH的一线治疗是硫唑嘌呤和皮质类固醇。然而,可能发生不良事件，这可以阻止疾病的缓解。在这些情况下,霉酚酸酯,巯基嘌呤,可以使用他克莫司。利妥昔单抗用于难以治疗的病例。西罗莫司是一种替代方案。然而,对它在AIH中的使用知之甚少。这是一个“难以治疗”AIH的具有挑战性的病例，使用西罗莫司和利妥昔单抗治疗，在其他药物的多次试验失败后。
